[A20-56] Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2020
Project no.:
A20-56
Commission:
Commission awarded on 30.06.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic colorectal cancer with a BRAF V600E mutation who have received prior systemic therapy
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-61 | Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |